TBK1 and Insulin resistance: Amlexanox, an inhibitor of IKKε and TANK-binding kinase 1 (TBK1), reduces inflammation and insulin resistance in obese mice9, prompting our exploration of IKKε in cardiac macrophages in an MI mouse model.